4.6 Review

Role of interleukin 8 in depression and other psychiatric disorders

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2020.110173

Keywords

Interleukin 8; Schizophrenia; Mood disorders; Alzheimer's disease; Cognition; Sleep

Funding

  1. Taiwan Ministry of Science and Technology [MOST 109-2634-F-075-001]
  2. Taipei Veterans General Hospital2 [V108D44-001-MY3-1, V109C-196, VGHUST109-V1-2-1]

Ask authors/readers for more resources

Low grade neuroinflammation, particularly involving interleukin-8 (IL-8), has been suggested as an underlying mechanism for various psychiatric diseases and cognitive disorders. Elevated peripheral levels of IL-8 have been reported in conditions such as schizophrenia, bipolar disorder, obstructive sleep apnea, and autism spectrum disorder. However, the exact role of IL-8 in major depression remains inconsistent in the literature.
Low grade neuroinflammation has been suggested as one of the underlying mechanisms of many psychiatric diseases as well as cognitive disorders. Interleukin 8 (IL-8), a proinflammatory cytokine produced by many cell types including macrophage and microglia, mainly functions as a neutrophil chemoattractant in the bloodstream. IL-8 is also found in the brain, where it is released from microglia in response to proinflammatory stimuli. In this review, we highlight studies focusing on the role of IL-8 in psychiatric diseases such as major depression, bipolar disorder, schizophrenia, sleep disorder, autism spectrum disorder, anxiety disorders and dementia. Increased peripheral IL-8 levels have been reported in these diseases, particularly in schizophrenic disorder, bipolar disorder, obstructive sleep apnea and autism spectrum disorder. The literature on IL-8 and major depression is inconsistent. IL-8 has been found to be a factor associated with schizophrenic prognosis and therapeutic response, and may affect a wide range of symptomatology. Considering that the exact role of immune alterations is still under research, the success of immune-based therapies in psychiatric diseases is limited for the time being.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available